Eric P Winer

List of Publications by Year
in descending order

		8181	3487
209	36,347	76	182
papers	citations	h-index	g-index

212	212	212	34018
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2018, 379, 2108-2121.	27.0	3,097
2	Breast Cancer Treatment. JAMA - Journal of the American Medical Association, 2019, 321, 288.	7.4	2,785
3	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2016, 375, 1738-1748.	27.0	1,390
4	Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal of Clinical Oncology, 2013, 31, 2382-2387.	1.6	998
5	CDK4/6 inhibition triggers anti-tumour immunity. Nature, 2017, 548, 471-475.	27.8	998
6	Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal of Medicine, 2004, 351, 971-977.	27.0	958
7	Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1145-1153.	1.6	860
8	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 44-59.	10.7	826
9	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821
10	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	27.0	789
11	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 2015, 33, 13-21.	1.6	782
12	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32, 3744-3752.	1.6	771
13	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 3764-3773.	7.0	733
14	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2014, 32, 2255-2269.	1.6	661
15	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine, 2014, 371, 107-118.	27.0	621
16	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine, 2015, 372, 134-141.	27.0	598
17	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications, 2017, 8, 1324.	12.8	584
18	Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing. Journal of Clinical Oncology, 2001, 19, 2875-2882.	1.6	574

#	Article	IF	Citations
19	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of Clinical Oncology, 2014, 32, 3483-3489.	1.6	543
20	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncology, The, 2014, 15, 1207-1214.	10.7	523
21	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine, 2016, 375, 209-219.	27.0	507
22	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature, 2016, 529, 413-417.	27.8	490
23	Clinicopathologic features, patterns of recurrence, and survival among women with tripleâ€negative breast cancer in the National Comprehensive Cancer Network. Cancer, 2012, 118, 5463-5472.	4.1	469
24	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 2018, 379, 122-137.	27.0	448
25	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1460-1468.	1.6	413
26	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2019, 37, 423-438.	1.6	384
27	Adjuvant Chemotherapy in Older and Younger Women With Lymph Nodeâ€“Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2005, 293, 1073.	7.4	371
28	Enzalutamide for the Treatment of Androgen Receptorâ€“Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 884-890.	1.6	365
29	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell, 2016, 29, 255-269.	16.8	356
30	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	1.2	354
31	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1902-1909.	1.6	351
32	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology, 2016, 34, 542-549.	1.6	336
33	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 2012, 30, 3234-3241.	1.6	319
34	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2078-2099.	1.6	303
35	Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. Journal of Clinical Oncology, 2016, 34, 3308-3314.	1.6	297
36	Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience. Journal of Clinical Oncology, 2007, 25, 3699-3704.	1.6	282

#	Article	IF	Citations
37	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	1.6	276
38	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 499-511.	10.7	260
39	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal of Clinical Oncology, 2017, 35, 1061-1069.	1.6	254
40	Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3840-3847.	1.6	253
41	Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology, 2016, 34, 1689-1701.	1.6	243
42	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal of Clinical Oncology, 2015, 33, 2254-2261.	1.6	232
43	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1868-1875.	1.6	229
44	Complications of axillary lymph node dissection for carcinoma of the breast. Cancer, 1998, 83, 1362-1368.	4.1	221
45	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2022, 386, 942-950.	27.0	220
46	CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878645.	3.2	218
47	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. Journal of Clinical Oncology, 2014, 32, 2142-2150.	1.6	207
48	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell, 2018, 33, 173-186.e5.	16.8	201
49	Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 2015, 33, 2361-2369.	1.6	197
50	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	10.7	191
51	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 2012, 133, 1057-1065.	2.5	183
52	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 1174-1193.	9.4	176
53	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 2015, 33, 701-708.	1.6	171
54	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. Journal of the National Cancer Institute, 2021, 113, 1005-1016.	6.3	171

#	Article	IF	Citations
55	Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5687-5695.	7.0	170
56	Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptorâ€“directed therapies. Nature Genetics, 2019, 51, 207-216.	21.4	170
57	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2021, 22, 212-222.	10.7	169
58	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2100-2108.	1.6	165
59	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 543-553.	1.6	162
60	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology, 2016, 34, 945-952.	1.6	148
61	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology, 2015, 33, 2772-2779.	1.6	141
62	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research, 2019, 21, 78.	5.0	141
63	Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 2565-2572.	7.0	138
64	Breast Cancer Treatment. JAMA - Journal of the American Medical Association, 2019, 321, 316.	7.4	115
65	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research, 2020, 26, 2556-2564.	7.0	109
66	Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2000, 18, 2710-2717.	1.6	108
67	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine, 2016, 22, 723-726.	30.7	105
68	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€“Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology, 2016, 34, 2602-2609.	1.6	101
69	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. Journal of Clinical Oncology, 2017, 35, 1008-1008.	1.6	99
70	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. Npj Breast Cancer, 2018, 4, 10.	5.2	95
71	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2804-2807.	1.6	93
72	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discovery, 2021, 11, 2474-2487.	9.4	92

#	Article	IF	Citations
73	Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clinical Cancer Research, 2016, 22, 3249-3259.	7.0	88
74	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of Clinical Oncology, 2022, 40, 282-293.	1.6	88
75	Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer, 2016, 122, 1169-1177.	4.1	87
76	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 5974-5989.	7.0	87
77	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptorâ€“Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Oncology, 2020, 6, 1598.	7.1	84
78	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxelâ€“Treated Advanced Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1733-1743.	6.3	83
79	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Annals of Surgical Oncology, 2015, 22, 3809-3815.	1.5	81
80	Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901. Journal of Clinical Oncology, 2014, 32, 2318-2327.	1.6	80
81	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer, 2016, 2, .	5.2	80
82	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist, 2017, 22, 25-32.	3.7	79
83	Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptorâ€“Positive Advanced Breast Cancerâ€”CALGB 40302 (Alliance). Journal of Clinical Oncology, 2014, 32, 3959-3966.	1.6	77
84	Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. Journal of Clinical Oncology, 2012, 30, 4071-4076.	1.6	76
85	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987.	7.0	76
86	The Immune Microenvironment in Hormone Receptorâ€“Positive Breast Cancer Before and After Preoperative Chemotherapy. Clinical Cancer Research, 2019, 25, 4644-4655.	7.0	76
87	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	1.6	76
88	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2020, 38, 4184-4193.	1.6	74
89	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clinical Cancer Research, 2018, 24, 5292-5304.	7.0	73
90	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). Journal of Clinical Oncology, 2014, 32, 2311-2317.	1.6	70

#	Article	IF	Citations
91	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 29.	7.1	68
92	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications, 2022, 13, .	12.8	68
93	Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. Clinical Cancer Research, 2018, 24, 1795-1804.	7.0	67
94	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060.	7.0	66
95	Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). Journal of Oncology Practice, 2014, 10, e285-e292.	2.5	65
96	Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage IIâ€“III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Research and Treatment, 2016, 160, 297-304.	2.5	63
97	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334.	1.6	62
98	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	5.0	60
99	IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2019, 37, 1003-1003.	1.6	59
100	Pharmacokinetics and clinical impact of all- trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemotherapy and Pharmacology, 1997, 40, 335-341.	2.3	55
101	Phase 2 study of pembrolizumab as first-line therapy for PD-L1â€“positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology, 2017, 35, 1088-1088.	1.6	55
102	Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal of the National Cancer Institute, 2015, 107, .	6.3	52
103	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021, 39, 2720-2731.	1.6	52
104	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of Clinical Oncology, 2015, 33, 2623-2631.	1.6	49
105	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expressionâ€“Based Meta-Analysis. Clinical Cancer Research, 2016, 22, 6039-6050.	7.0	48
106	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research, 2018, 20, 109.	5.0	48
107	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer, 2021, 2, 34-48.	13.2	48
108	I-SPY 2 â€” Toward More Rapid Progress in Breast Cancer Treatment. New England Journal of Medicine, 2016, 375, 83-84.	27.0	47

#	Article	IF	Citations
109	Breast cancerâ€specific survival by age: Worse outcomes for the oldest patients. Cancer, 2018, 124, 2184-2191.	4.1	46
110	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Investigational New Drugs, 2015, 33, 1108-1114.	2.6	44
111	Androgen Receptor Expression and Breast Cancer Survival: Results From the Nursesâ€™ Health Studies. Journal of the National Cancer Institute, 2019, 111, 700-708.	6.3	44
112	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 238-245.	2.4	44
113	Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer, 2008, 112, 700-709.	4.1	43
114	Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.. Journal of Clinical Oncology, 2020, 38, 1013-1013.	1.6	42
115	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2408-2419.	1.6	42
116	Is Axillary Lymph Node Dissection Indicated for Early-Stage Breast Cancer? A Decision Analysis. Journal of Clinical Oncology, 1999, 17, 1465-1465.	1.6	41
117	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Research and Treatment, 2016, 160, 305-312.	2.5	37
118	Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. Oncologist, 2019, 24, e441-e449.	3.7	36
119	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2019, 37, 714-722.	1.6	36
120	Perils of the Pathologic Complete Response. Journal of Clinical Oncology, 2016, 34, 3959-3962.	1.6	35
121	TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).. Journal of Clinical Oncology, 2020, 38, 1002-1002.	1.6	35
122	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of Clinical Oncology, 2022, 40, 438-448.	1.6	35
123	Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy. Cancer, 2005, 104, 1580-1589.	4.1	34
124	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2020, 80, PD5-03-PD5-03.	0.9	34
125	Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology, 2022, 24, 316-326.	10.3	34
126	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal of Clinical Oncology, 2020, 38, 4120-4129.	1.6	32

#	Article	IF	Citations
127	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clinical Cancer Research, 2022, 28, 1258-1267.	7.0	31
128	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	30
129	Localâ€“regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research and Treatment, 2019, 176, 303-310.	2.5	30
130	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. Journal of Clinical Oncology, 2020, 38, 504-504.	1.6	30
131	Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. , 1999, 8, 167-176.		29
132	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 6149-6157.	7.0	29
133	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 983-991.	7.0	29
134	Quality-of-life research in patients with breast cancer. Cancer, 1994, 74, 410-415.	4.1	27
135	Surveillance Mammography in Older Patients With Breast Cancerâ€”Can We Ever Stop?. JAMA Oncology, 2017, 3, 402.	7.1	27
136	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer, 2019, 19, 399-404.	2.4	27
137	Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Breast, 2015, 24, S132-S135.	2.2	26
138	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Research and Treatment, 2020, 179, 113-123.	2.5	26
139	Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer, 2008, 15, 31-34.	2.9	24
140	Genomic Characterization of de novo Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1105-1118.	7.0	24
141	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology, 2021, 39, 2247-2256.	1.6	22
142	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 1493-1499.	7.0	22
143	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clinical Breast Cancer, 2020, 20, 145-151.e2.	2.4	21
144	The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer. JCI Insight, 2021, 6, .	5.0	20

#	Article	IF	Citations
145	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	5.2	20
146	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology, 2020, 38, 500-500.	1.6	20
147	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. Oncologist, 2015, 20, 713-718.	3.7	19
148	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	12.8	19
149	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. Npj Breast Cancer, 2022, 8, 63.	5.2	18
150	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prevention Research, 2020, 13, 1055-1062.	1.5	17
151	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. Clinical Breast Cancer, 2014, 14, 413-416.	2.4	16
152	Timeliness in Breast Cancer Treatmentâ€"The Sooner, the Better. JAMA Oncology, 2016, 2, 302.	7.1	16
153	A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).. Journal of Clinical Oncology, 2020, 38, 1046-1046.	1.6	16
154	Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Annals of Surgical Oncology, 2015, 22, 4280-4286.	1.5	15
155	De-escalating Breast Cancer Surgeryâ€"Where Is the Tipping Point?. JAMA Oncology, 2020, 6, 183.	7.1	15
156	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. JAMA Oncology, 2021, 7, 609.	7.1	15
157	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. JNCI Cancer Spectrum, 2020, 4, pkz096.	2.9	14
158	The Global Landscape of Treatment Standards for Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1143-1155.	6.3	13
159	Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer. Breast Disease, 2001, 14, 41-50.	0.8	12
160	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia, 2022, 36, 210-220.	7.2	12
161	Informed Consent for BRCA1 and BRCA2 Testing. Breast Disease, 1998, 10, 99-114.	0.8	11
162	A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. Journal of Geriatric Oncology, 2013, 4, 353-361.	1.0	11

#	Article	IF	Citations
163	ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS597-TPS597.	1.6	11
164	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 117-124.	0.8	11
165	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Annals of Oncology, 2022, 33, 234-238.	1.2	11
166	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	3.0	11
167	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Research and Treatment, 2021, 185, 215-227.	2.5	10
168	Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer, 2021, 21, 568.	2.6	10
169	Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. Journal of the National Cancer Institute, 2021, 113, 355-359.	6.3	10
170	p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications, 2022, 13, 1473.	12.8	10
171	The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage IIâ€“III and metastatic breast cancers. Breast Cancer Research and Treatment, 2022, 194, 65-78.	2.5	10
172	Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1â€“ metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2021, 39, TPS1106-TPS1106.	1.6	9
173	Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist, 2015, 20, 992-1000.	3.7	8
174	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multiâ€institutional study. Cancer, 2015, 121, 1937-1948.	4.1	8
175	Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). Journal of the American College of Surgeons, 2017, 224, 688-694.	0.5	8
176	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectrum, 2021, 5, pkab025.	2.9	8
177	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. Journal of Clinical Oncology, 2020, 38, 1005-1005.	1.6	8
178	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
179	Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. Clinical Breast Cancer, 2020, 20, 395-401.e3.	2.4	7
180	Expanding Criteria for Prognostic Stage IA in Hormone Receptorâ€“Positive Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1744-1750.	6.3	7

#	Article	IF	Citations
181	T-DM1 â€" an important agent in the history of breast cancer management. Nature Reviews Clinical Oncology, 2017, 14, 651-652.	27.6	6
182	Predicting breast cancer therapeutic response. Nature Medicine, 2018, 24, 535-537.	30.7	6
183	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, e20-e26.	2.4	5
184	A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 45-52.	0.8	5
185	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2021, 5, 1777-1787.	3.0	5
186	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast, 2016, 30, 136-140.	2.2	4
187	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. Npj Breast Cancer, 2021, 7, 98.	5.2	4
188	Inability to escalate vinorelbine dose intensity using a daily Ã— 3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 1999, 43, 68-72.	2.3	3
189	Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 316-324.	4.9	3
190	Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain?. Journal of the National Cancer Institute, 2020, 112, 551-552.	6.3	3
191	Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119. , 2021, , .		3
192	Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2021, 39, TPS1102-TPS1102.	1.6	3
193	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situâ€"Reply. JAMA Oncology, 2020, 6, 1118.	7.1	3
194	Perceptions of patients with early stage breast cancer toward research biopsies. Cancer, 2021, 127, 1208-1219.	4.1	3
195	Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. JCO Oncology Practice, 2022, 18, e1447-e1453.	2.9	3
196	Case 32-2007. New England Journal of Medicine, 2007, 357, 1640-1648.	27.0	2
197	Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature. Cancer Treatment Communications, 2015, 4, 41-45.	0.4	2
198	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. Journal of Cellular and Molecular Medicine, 2020, 24, 2145-2156.	3.6	2

#	Article	IF	Citations
199	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2â^' breast cancer. Cancer Research, 2022, 82, GS2-01-GS2-01.	0.9	2
200	Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. Journal of the National Cancer Institute, 2018, 110, 443-445.	6.3	1
201	ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS600-TPS600.	1.6	1
202	Reply to S. Sorscher. Journal of Clinical Oncology, 2017, 35, 1746-1747.	1.6	0
203	Temporal and spatial topography of cell proliferation in cancer.. Journal of Clinical Oncology, 2021, 39, 3122-3122.	1.6	0
204	Survival in male breast cancer (MaBC) over the past three decades.. Journal of Clinical Oncology, 2021, 39, 569-569.	1.6	0
205	Reply to M. Tanaka et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01967.	1.6	0
206	Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.. Journal of Clinical Oncology, 2020, 38, 514-514.	1.6	0
207	Genomic profiling of breast cancer brain metastases reveals targetable alterations.. Journal of Clinical Oncology, 2020, 38, 2525-2525.	1.6	0
208	Expanding criteria for prognostic stage IA disease in HR+ breast cancer.. Journal of Clinical Oncology, 2020, 38, 550-550.	1.6	0
209	The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. Clinical Advances in Hematology and Oncology, 2008, 6, 573-4.	0.3	0